{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:59:41Z","timestamp":1779217181888,"version":"3.51.4"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,25]]},"DOI":"10.7759\/cureus.105848","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:23:51Z","timestamp":1774459431000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinical Challenges in Profound Thrombocytopenia Associated With Type 2 Heparin-Induced Thrombocytopenia (HIT2)"],"prefix":"10.7759","author":[{"given":"Brielle","family":"Coe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman","family":"Elkhashab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A","family":"Saldarriaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brianna","family":"Cattelino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Thrombocytopenia: Evaluation and management","volume":"106","author":"Gauer RL","year":"2022","unstructured":"Gauer RL, Whitaker DJ. Thrombocytopenia: Evaluation and management. Am Fam Physician. 2022, 106:288-98.","journal-title":"Am Fam Physician"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker A","year":"2018","unstructured":"Cuker A, Arepally GM, Chong BH, et al.. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018, 2:3360-92. 10.1182\/bloodadvances.2018024489","journal-title":"Blood Adv"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2005.03.032","article-title":"Uremic bleeding: pathophysiology and clinical risk factors","volume":"118","author":"Sohal AS","year":"2006","unstructured":"Sohal AS, Gangji AS, Crowther MA, Treleaven D. Uremic bleeding: pathophysiology and clinical risk factors. Thrombosis Research. 2006, 118:417-22.","journal-title":"Thrombosis Research"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2025.03.038","article-title":"Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation","volume":"23","author":"Iba T","year":"2025","unstructured":"Iba T, Levy JH, Maier CL, et al.. Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation. J Thromb Haemost. 2025, 23:2356-62. 10.1016\/j.jtha.2025.03.038","journal-title":"J Thromb Haemost"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-061813-013241","article-title":"ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura","volume":"66","author":"Zheng XL","year":"2015","unstructured":"Zheng XL. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med. 2015, 66:211-25. 10.1146\/annurev-med-061813-013241","journal-title":"Annu Rev Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03025.x","article-title":"Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays","volume":"6","author":"Warkentin TE","year":"2008","unstructured":"Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008, 6:1304-12. 10.1111\/j.1538-7836.2008.03025.x","journal-title":"J Thromb Haemost"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Linkins LA","year":"2012","unstructured":"Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012, 141:e495S-530S. 10.1378\/chest.11-2303","journal-title":"Chest"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/393398-clinical-challenges-in-profound-thrombocytopenia-associated-with-type-2-heparin-induced-thrombocytopenia-hit2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:23:52Z","timestamp":1774459432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/393398-clinical-challenges-in-profound-thrombocytopenia-associated-with-type-2-heparin-induced-thrombocytopenia-hit2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.105848","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,25]]}}}